Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Na.H2O4P |
| Molecular Weight | 120.9772 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].O[32P](O)([O-])=O
InChI
InChIKey=AJPJDKMHJJGVTQ-ZYUMTRPDSA-M
InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1/i;5+1
| Molecular Formula | H2O4P |
| Molecular Weight | 97.9874 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:20:04 GMT 2025
by
admin
on
Mon Mar 31 21:20:04 GMT 2025
|
| Record UNII |
FEB963GEFV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1446
Created by
admin on Mon Mar 31 21:20:04 GMT 2025 , Edited by admin on Mon Mar 31 21:20:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C185463
Created by
admin on Mon Mar 31 21:20:04 GMT 2025 , Edited by admin on Mon Mar 31 21:20:04 GMT 2025
|
PRIMARY | |||
|
8027-28-9
Created by
admin on Mon Mar 31 21:20:04 GMT 2025 , Edited by admin on Mon Mar 31 21:20:04 GMT 2025
|
PRIMARY | |||
|
FEB963GEFV
Created by
admin on Mon Mar 31 21:20:04 GMT 2025 , Edited by admin on Mon Mar 31 21:20:04 GMT 2025
|
PRIMARY | |||
|
23694678
Created by
admin on Mon Mar 31 21:20:04 GMT 2025 , Edited by admin on Mon Mar 31 21:20:04 GMT 2025
|
PRIMARY |